# US 10,117,904 B2 · Use of anti-bacterial agents for the treatment of epithelial-related conditions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,117,904 B2 - Document ID: US10117904B2 - Status: Granted - Kind: B2 - Application number: 15/221,380 - Filed: 2016-07-27 - Published: 2017-02-23 - Granted: 2018-11-06 - Earliest claimed: 2009-11-12 - Assignees: Signum Biosciences, Inc. - Applicants: Signum Biosciences, Inc. - Inventors: Jeffry B. Stock; Maxwell Stock - Web page: https://patentgrep.com/patent/US10117904B2 ## CPC - A61K 38/05: Dipeptides - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/007: {Pulmonary tract; Aromatherapy} - A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine - A61K 31/381: having five-membered rings - A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin - A61K 31/5375: 1,4-Oxazines, e.g. morpholine - A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis - A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants - A61P 9/00: Drugs for disorders of the cardiovascular system - A61P 11/00: Drugs for disorders of the respiratory system - A61P 11/02: Nasal agents, e.g. decongestants - A61P 11/14: Antitussive agents - A61P 13/00: Drugs for disorders of the urinary system - A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers - A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives - A61P 15/02: for disorders of the vagina - A61P 17/00: Drugs for dermatological disorders - A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like - A61P 17/04: Antipruritics - A61P 17/06: Antipsoriatics - A61P 17/08: Antiseborrheics - A61P 17/10: Anti-acne agents - A61P 21/00: Drugs for disorders of the muscular or neuromuscular system - A61P 27/02: Ophthalmic agents - A61P 27/16: Otologicals - A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 31/06: for tuberculosis - A61P 35/00: Antineoplastic agents - A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Disclosed herein are methods of inactivating and/or decolonizing bacteria on a surface. The present invention also discloses methods for treatment of epithelial conditions caused or aggravated by bacteria, such as acne vulgaris, in a subject in need thereof. The present invention additionally discloses inventive compounds and compositions that exhibit anti-bacterial and/or anti-inflammatory effects. ## Claims ### Claim 1 A method of treating or ameliorating the symptoms of acne comprising steps of: administering to a subject in need thereof an effective amount of a compound selected from the group consisting of: and pharmaceutically acceptable salts of each of the foregoing. ### Claim 2 (depends on 1) The method according to claim 1, wherein the compound exhibits an anti-inflammatory activity and an anti-bacterial activity. ### Claim 3 (depends on 1) The method according to claim 1, wherein administration is topical. ### Claim 4 (depends on 1) The method according to claim 1, wherein administration is by inhalation. ### Claim 5 (depends on 1) The method according to claim 1, wherein administration is parenteral. ### Claim 6 (depends on 1) The method according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 7 (depends on 1) The method according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 8 (depends on 1) The method according to claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 9 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 10 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 11 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 12 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 13 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 14 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 15 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 16 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof. ### Claim 17 (depends on 1) The method of claim 1, wherein the compound is: or a pharmaceutically acceptable salt thereof.